Therapy Shows Promise in Children with Metastatic Gastrointenstinal Stromal Tumor

Armen Hareyan's picture
Advertisement

Digestive-Tract Cancer Therapy

Children with a rare digestive-tract cancer that is resistant to front-line therapy have benefited from a newer targeted therapy that has been shown effective in adults, according to data from a small pilot study that Dana-Farber Cancer Institute researchers will present at the American Society of Clinical Oncology's annual meeting in Atlanta on Sunday, June 4, at 9 a.m. (Building C, Level 3, Room C306).

Investigators led by Katherine Janeway, MD, and George Demetri, MD, of the Ludwig Center for Cancer Research at Dana-Farber will discuss results of a preliminary clinical trial in which three children -- two teenagers and a pre-teen -- with metastatic Gastrointenstinal Stromal Tumor (GIST) resistant to imatinib (Gleevec

Advertisement